Dear John,

ICYMI, Health Affairs released a Health Policy brief from Nathaniel Tran and Gilbert Gonzales exploring how public debates and enactments of both pro- and anti-LGBTQI+ policies affect LGBTQI+ populations in the places where they live, learn, work, play, and age.

Today's Featured Articles

Variation In Hospital Salary Expenditures And Utilization Changes After Private Equity Acquisition, 2005–19

Sneha Kannan and Zirui Song

The End Of The MA Value-Based Insurance Design Model: What Next?

Riya Doshi and A. Mark Fendrick

part of our Supplemental Benefits In Medicare Advantage series

What Lies Ahead For Medicaid In Budget Reconciliation?

Sara Rosenbaum and Alison Barkoff

part of our Health Policy at a Crossroads series

An Agenda For Sickle Cell Disease Research That Encompasses Lived Experience

Betty S. Pace and Titilope Faspie

part of our The Future of Sickle Cell Disease Research & Care series

More on Private Equity Acquisition

Private Equity In Health Care: A State-Based Policy Perspective

Stephanie S. Lee et al. (November 2024)

Protecting Patients And Society In An Era Of Private Equity Provider Ownership: Challenges And Opportunities For Policy

Christopher Cai and Zirui Song (May 2024)

Financial Impacts And Operational Implications Of Private Equity Acquisition Of US Hospitals

Marcello Cerullo et al. (April 2022)

Jennifer Wolff on The Growing Number of Family Caregivers for Older Adults

Health Affairs' Senior Deputy Editor Rob Lott interviews Jennifer Wolff of John Hopkins University about her recent paper that explores the increasing number of family caregivers that are assisting older US adults, including adults with dementia.

New Drugs at the Medicare Negotiating Table with Stacie Dusetzina

Join Health Affairs on February 25 for an exclusive Insider virtual event exploring HHS’s announcement of the 15 additional drugs selected for Medicare drug price negotiations, including weight-loss drugs such as Ozempic and Wegovy.

Stacie Dusetzina of Vanderbilt University Medical Center and Health Affairs Insider newsletter writer joins Health Affairs’ Laura Tollen to get Insiders up to speed on this round of drugs, the negotiation process to come, and what to expect in the second Trump administration.